Weight-loss drug before hernia surgery cuts complications in obese patients
NCT ID NCT07638592
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a 16-week weight-loss program using the drug tirzepatide before elective hernia surgery in 91 adults with obesity. Participants lost an average of 13.8% of their body weight, and all reached the target weight needed for surgery. Compared to a similar group who had surgery without the drug, those who took tirzepatide had fewer wound problems after the operation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREHABILITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Francesco Pizza
Naples, 80131, Italy